Skip to main content

Table 4 Clinical features of the study patients according to use of empiric antibiotic therapy at IMDC onset (No. of patients with IMDC = 434)

From: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

FeatureAntibiotic therapy at IMDC onset (n = 41)No antibiotic therapy (n = 393)p
Immunosuppressive therapy for IMDC, n (%)41 (100.0)235 (59.8)< 0.001
Median duration of IMDC symptoms, days (IQR)17 (8–32)8 (3–19)0.888
Hospitalization, n (%)41 (100)190 (48.3)< 0.001
Median duration of hospitalization, days (IQR)9 (4–15)5 (3–8)0.003
ICU admission, n (%)3 (7.3)8 (2.0)0.076
Grade of colitis, n (%)0.001
 16 (14.6)68 (24.5) 
 212 (29.3)138 (49.6) 
 322 (53.7)62 (22.3) 
 41 (2.4)10 (3.6) 
Grade of diarrhea, n (%)< 0.001
 14 (9.8)125 (31.8) 
 28 (19.5)112 (28.5) 
 324 (58.5)140 (35.6) 
 45 (12.2)16 (4.1) 
Median duration of steroid administration, days (IQR)39 (23–64)45 (23–70)0.496
Intravenous steroid administration, n (%)35 (85.4)112 (50.2)< 0.001
Infliximab/vedolizumab administration, n (%)18 (43.9)65 (16.5)< 0.001
Recurrence of IMDC, n (%)13 (31.7)70 (17.8)0.038
Colon perforation, n (%)1 (2.4)6 (1.5)0.503